Abbott Laboratories delivered first-quarter financial results on April 16 that exceeded Wall Street’s revenue projections, with its recently completed cancer diagnostics acquisition providing additional momentum.
The healthcare giant posted adjusted earnings per share of $1.15 for the three-month period. This figure aligned with one analyst projection of $1.15 and exceeded an alternative consensus estimate of $1.14 by one cent, varying by data provider.
Quarterly revenue reached $11.16 billion, outpacing the $11 billion Wall Street anticipated.
Shares settled at $101.56 prior to the earnings announcement. ABT has declined 16.59% during the preceding three-month period and dropped 22.46% year-over-year.
The Exact Sciences transaction influenced this quarter’s financial performance. Abbott finalized an agreement to acquire the cancer diagnostics firm in November at $105 per share, representing a transaction valued at approximately $23 billion. The acquisition completed in March 2026.
This transaction represents among Abbott’s most significant acquisitions and signals an aggressive expansion into oncology diagnostics. The newly integrated unit’s performance contributed meaningfully to the first-quarter revenue outperformance.
Abbott’s medical device division continues as its primary revenue generator. The segment delivered solid results in Q1, supporting the overall revenue outperformance.
The healthcare company has consistently relied on its device operations as a fundamental growth engine for multiple consecutive quarters. This pattern persisted throughout the initial three months of 2026.
Looking ahead to Q2 2026, Abbott provided EPS guidance ranging from $1.25 to $1.31. Wall Street’s consensus estimate stands at $1.32, positioning Abbott’s guidance midpoint slightly below analyst targets.
For the complete fiscal year, Abbott projects EPS between $5.38 and $5.58. The Street consensus of $5.47 falls comfortably within this projected range.
Abbott experienced zero upward EPS estimate revisions and 18 downward revisions over the past 90 days. This represents a deterioration from the previous quarter’s “great performance” financial health assessment — InvestingPro currently assigns Abbott a “good performance” financial health rating.
The revenue outperformance provides some confidence, despite guidance that didn’t completely satisfy market expectations. Abbott’s Q1 top-line execution represented the stronger component of this quarterly report.
The full-year EPS consensus of $5.47 remains within Abbott’s projected range of $5.38 to $5.58, providing the company flexibility to meet or exceed that benchmark throughout the remainder of the fiscal year.
The post Abbott Laboratories (ABT) Q1 2026 Results: Revenue Surpasses Expectations on Cancer Diagnostics Strength appeared first on Blockonomi.
